Stay updated with breaking news from Program Ceiling Price. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Late last week, the Health and Resources Services Administration (HRSA) sent a letter to Merck warning that it may be dealt monetary penalties for allegedly refusing to give 340B discounts to covered entities. HRSA first contacted Merck about the matter in May, when the agency instructed the biopharmaceutical company to comply with 340B statutory obligations, and immediately
The Health Resources andServices Administration (HRSA) has sent a letter to Boehringer Ingelheim ordering the pharmaceutical company to comply with federal requirements under the 340B drug pricing program. HRSA informed the company that its August 1 policy cutting off discounted pricing to hospitals on drugs dispensed at community-based pharmacies is unlawful. The agency
Photo: Jeff Lagasse/Healthcare Finance News Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter sent to the drugmakers this week from the Health Resources and Services Administration. The HRSA maintained that the drug manufacturers in question – AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi and United Therapeutics – placed restrictions on the 340B program for hospitals that dispense drugs through contract pharmacies, and these restrict...